The Power of Truth® has been released for sale and assignment to a conservative pro-American news outlet, cable network, or other media outlet that wants to define and brand its operation as the bearer of the truth, and set itself above the competition.

In every news story the audience hears of censorship, speech, and the truth. The Power of Truth® has significant value to define an outlet, and expand its audience. A growing media outlet may decide to rebrand their operation The Power of Truth®. An established outlet may choose to make it the slogan distinguishing their operation from the competition. You want people to think of your outlet when they hear it, and think of the slogan when they see your company name. It is the thing which answers the consumer's questions: Why should I choose you? Why should I listen to you? Think:

  • What’s in your wallet -- Capital One
  • The most trusted name in news – CNN
  • Fair and balanced - Fox News
  • Where’s the beef -- Wendy’s
  • You’re in good hands -- Allstate
  • The ultimate driving machine -- BMW

The Power of Truth® is registered at the federal trademark level in all applicable trademark classes, and the sale and assignment includes the applicable domain names. The buyer will have both the trademark and the domains so that it will control its business landscape without downrange interference.

Contact: Truth@ThePowerOfTruth.com

Connective tissue is found throughout the human body, within and between structures as varied as muscles, nerves and internal organs. Like an elaborate web, it holds everything together – providing the body shape and promoting proper movement.

Many people, especially young women, have very flexible connective tissue. While flexibility is essential for childbirth – and an advantage to dancers and gymnasts – fragile and stretchy connective tissue can sometimes lead to a variety of health problems.

Overly mobile joints are prone to injuries[1] like sprained ankles, dislocated shoulders and chronic neck pain. Hypermobile connective tissue can also cause serious health problems throughout the body[2], including the gut, nerves, skin, urinary tract and even immune system.

Many health care providers, especially in the U.S.[3], have not been trained to look for problems related to hypermobility, which means it often takes people with hypermobile connective tissue disorders a decade or more to be diagnosed[4]. Although many clinicians were taught that connective tissue disorders are rare, current estimates suggest that as much as 2% of the overall population experiences symptoms[5] related to hypermobility, and around a third of people treated[6] in pain management or rheumatology clinics may be hypermobile.

I’m a physical therapist and researcher[7] who specializes in treating conditions arising from hypermobility. When I tell patients their years of symptoms are real, can be explained and are potentially manageable, some have cried with relief.

Wide range of symptoms

Symptomatic generalized joint hypermobility is the most inclusive term for conditions caused by hypermobile connective tissue. While some forms have genetic markers, more than 90% of hypermobility conditions[8] – including hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder – do not. They are diagnosed by a physical exam using a diagnostic checklist[9]. Symptoms and severity can differ greatly from person to person and vary over time.

Two pie chart graphics, one labeled Person 1, the other Person 2. Each depicts a very different profile of symptoms - and severity of symptoms.
Two people with hypermobility syndrome disorder may experience very different symptoms. One person may have severe joint instability, fatigue and autonomic dysfunction. Another person may have mild joint instability but severe headaches and gastrointestinal issues. The Ehlers-Danlos Society[10], CC BY-ND[11]

Symptoms can include widespread pain and frequent injury, irritable bowel syndrome, indigestion, hernias, frequent bruising and poor skin healing, trouble breathing, migraines and headaches, dizziness, fatigue, insomnia, anxiety and trouble concentrating.

Some of these problems are purely mechanical, such as fragile skin[12] that tears easily and heals poorly, stretchy gut tissue[13] that doesn’t move along digesting food as quickly as it should and excessive mobility between the skull and top vertebra that can compress the brain stem and lead to central nervous system problems[14].

Additionally, people with hypermobility conditions have problems that scientists don’t yet understand. For example, the autonomic nervous system – which regulates functions like digestion, breathing and heart rate – is out of balance[15]. Similarly, research has not fully explained the connection between hypermobility and mast cells, which are part of the immune system protecting against viruses and other invaders. One hypothesis is that overactive mast cells[16] may release chemicals affecting surrounding connective tissue.

Often, multiple factors contribute to a given symptom. For example, the problem of insomnia[17] is due, in part, to pain that keeps people awake. But lax tissue in the throat can cause sleep apnea, as well. What’s more, an overactive nervous system and anxiety about unexplained health issues can also lead to poor sleep.

Ehlers-Danlos syndrome is the most common heritable connective tissue disorder. It was first described by Hippocrates in 400 BCE[18] but was formally defined by doctors Edvard Ehlers and Henri-Alexandre Danlos in the early 1900s. About 90% of all Ehlers-Danlos[19] patients have the hypermobile type.

Doctors have traditionally considered hypermobile Ehlers-Danlos syndrome a rare condition, which is how people with hypermobility came to be called zebras[20]. Medical students are taught, “When you hear hoofbeats, look for horses, not zebras,” as a reminder that rare conditions are seldom seen, and virtually all hoofbeats indicate horses. Hypermobility experts now believe Ehlers-Danlos syndrome is not as rare as previously thought – and many people are misdiagnosed or undiagnosed[21].

Difficulties with diagnosis

Lack of a diagnosis can be frightening and discouraging for people with hypermobility spectrum disorder. Patients are often told nothing is wrong with them and they are just complaining too much or have low pain tolerance. Many may be considered difficult patients, because they see multiple health care providers trying to understand their symptoms – and often present with complaints that vary from day to day.

Some providers believe their patients but simply do not know how to manage their problems. Other patients report being subjected to medical gaslighting[22], being told repeatedly, “It’s all in your head.” Women are more likely[23] to be told that their problems are psychiatric rather than physiologic. Hypermobile patients frequently feel abandoned by the health care system[24].

Even once diagnosed, hypermobile patients often struggle to find knowledgeable providers who can help rather than make problems worse. A 2022 study[25] showed only 9% of physicians were familiar with the diagnostic criteria for hypermobile Ehlers-Danlos syndrome – and only 4% reported feeling comfortable treating it.

Failure to diagnose underlying hypermobility can lead to inappropriate treatments[26], such as unhelpful medications, surgeries that might be less effective for hypermobile patients or even inappropriate psychiatric diagnoses. A delayed diagnosis leads to worse function, increased pain and disability[27].

How physical therapy can help hypermobility

There is no cure for the actual connective tissue abnormality. So, treatment strives to minimize pain and injury while improving joint stability, overall health and daily function.

A woman's arm is flexed beyond straight at the elbow.
A hyperextended elbow. Veronica Foale/Flickr[28], CC BY-NC-SA[29]

Joints normally provide sensory information about where the body is in space, but this system does not function properly[30] in hypermobile people, who often do not realize joints are moving in ways they should not. Although research is limited, existing research suggests that physical therapy can improve[31] sensory awareness and motor control – and help patients identify, activate and strengthen stabilizing muscles.

Since many hypermobile patients have sensitive nervous systems, systemic calming is an important part of pain relief. Patient education, movement, sleep, mind-body training and nutrition can also help manage pain[32] with minimal medication.

Occupational therapy[33] can also benefit hypermobile patients through environmental modifications, activity pacing and assistive and mobility devices like splints, braces and wheelchairs.

Other management approaches include nutrition[34], psychosocial support and medical management[35] through medications and surgery. Orthopedic surgeries appear to be less successful in hypermobile people[36] compared with nonhypermobile people, so nonsurgical options should be explored before considering surgery.

Symptomatic generalized joint hypermobility is a complicated condition that is not yet fully understood. Once it has been identified, though, many strategies can help decrease pain and injuries – and improve function and quality of life.

Read more …Overly flexible connective tissue causes problems in joints and throughout the body − and is often...

The Biden administration released on Aug. 29, 2023, a list of the first 10 drugs[1] that will be up for negotiations with pharmaceutical companies over their Medicare prices.

The drugs are purchased through Medicare Part D[2], a prescription drug coverage program for Americans ages 65 and older. The 10 medications accounted for more than US$50.5 billion in gross costs between June 1, 2022, and May 31, 2023.

Provisions authorizing these negotiations were part of the Inflation Reduction Act[3] which Congress passed in 2022, allowing Medicare to negotiate drug prices for the first time. Pending successful negotiations, these changes would amount to what researchers estimated to be net savings of about $1.8 billion in 2026[4]. The Congressional Budget Office projected an even bigger savings of $3.7 billion[5].

The top 10 list includes such drugs as Johnson & Johnson’s Xarelto[6], which treats blood clots, and Amgen’s Enbrel[7], which treats rheumatoid arthritis and psoriasis.

Negotiations are expected to begin in October and continue until August 2024, with lower prices going into effect in 2026.

Democrats have hailed the new law’s drug pricing provisions as game-changing[8]. They’re likely to make the issue a centerpiece of their 2024 election campaigns[9]. Democrats are further emboldened as public opinion polls show overwhelming support for the policy among Americans[10].

As a scholar who researches the politics of health policy[11], I’m skeptical that Medicare drug price negotiations will end up making as big a difference as Democrats have promised, at least in the near future. While U.S. prescription drug prices are excessive, the true potential of the policy is unclear, as it remains muddled in lawsuits[12] and industry opposition[13]. However, if it can withstand the ongoing attacks and become settled law, Americans ages 65 and up could see real financial relief down the line.

Cutting drug costs for Medicare enrollees

The Inflation Reduction Act[14] allows the Centers for Medicare & Medicaid Services to negotiate prices with the companies that make some of the most expensive drugs in the Medicare program, including life-saving cancer and diabetes treatments like Imbruvica[15] and Januvia[16].

If the negotiations proceed as planned, the drug-price-negotiation provision is expected to save the U.S. government about $98.5 billion[17] by 2031 by allowing it to pay less on prescription drugs for Americans on Medicare – nearly 66 million people[18]. The Biden administration hopes that these cost savings will be passed down to Americans 65 and older through reduced Medicare Part D premiums[19] and lower out-of-pocket costs.

The Inflation Reduction Act provides additional benefits for older Americans[20], including limiting their out-of-pocket expenses for prescription drugs to no more than $2,000 annually, limiting the growth of Medicare Part D premiums, eliminating out-of-pocket costs for vaccines and providing premium subsidies to low-income people ages 65 and older.

The Inflation Reduction Act also includes a separate provision that requires drugmakers, under certain conditions, to provide the Medicare program[21] with rebates if drug price increases outpace inflation, starting in January of 2023[22]. That measure is expected to yield $71 billion in savings[23] over a decade.

A Black female pharmacist shows Black woman some prescription medications.
Government negotiations with pharmaceutical companies over drug pricing should lower medical costs for many people ages 65 and older. Marko Geber/DigitalVision via Getty Images[24]

Penalties for companies that won’t negotiate

The 10 drugs that the Centers for Medicare & Medicaid Services have selected[25] accounted for $3.4 billion in out-of-pocket spending in 2022 for Americans ages 65 and older[26] and $50.5 billion, or about 20%, of total Part D gross prescription drug costs[27] from June 1, 2022, to May 31, 2023.

Pharmaceutical companies have to sign agreements to participate in the upcoming negotiations by October 2023. Based on criteria such as public feedback and consultation, as well as the clinical value of the drug, the Centers for Medicare & Medicaid Services will make an initial price offer in early 2024, with the potential to further negotiate the price until August 2024[28]. Going forward, additional drugs will be subject to negotiations.

If drugmakers don’t negotiate, they will face stiff penalties in the form of a tax, reaching as high as 95% of U.S. pharmaceutical product sales[29]. Alternatively, the companies may pull their drugs from the Medicare and Medicaid markets, meaning that seniors on Medicare would lose access to them.

Why US drug prices are so high

Americans pay substantially more for prescription drugs[30] compared with people who live in countries with similar economies, like Germany, the U.K. and Australia. While Americans spent more than $1,100 a year[31] in 2019, Germans paid $825, the British paid $285 and Australians paid $434 per person.

The reasons for this disparity are multilayered[32] and include the overall complexity of the U.S. health care system[33] and the lack of transparency in the drug supply chain[34]. Of course, many other countries also directly set prices for drugs or use their monopoly on health services to drive down costs[35].

For example, Dulera, an asthma drug, costs 50 times more in the U.S.[36] than the international average. Januvia, a diabetes drug that is among the first 10 drugs up for price negotiation, and Combigan, a glaucoma drug, cost about 10 times more[37].

These costs impose a big burden on Americans[38]1 in 5 of whom[39] skip at least some of their prescribed medications due to the expense. Those 65 and older are particularly affected[40] by these problems.

Older adult customer standing at a pharmacy checkout stand, with pharmacist explaining something.
The first 10 drugs selected for negotiated pricing can be picked up at a pharmacy. Maskot/Getty Images[41]

Strong resistance

It’s too soon to say how big the impact of the drug pricing provisions will be and whether this policy will be sustained.

Drugmakers have opposed any governmental regulation of drug prices for decades[42]. They are fighting the measure in court[43] and running a public relations campaign that warns of reduced investments in life-saving cures because their financial incentives are reduced.

Even if the drug price negotiations survive the industry’s legal challenges, it’s possible that future Republican administrations won’t embrace or enforce this policy. This is because potential Republican wins in the 2024 presidential and congressional elections could unravel or severely curtail the new drug negotiation policy. Indeed, Republicans have been working feverishly on designing a strategy[44] to use the negotiations against Democrats in the upcoming elections.

If successful, the price negotiations could substantially lower the cost of some of the most in-demand drugs.

Weighing the prospects

In my view, the government’s efforts to cut prices for prescription drugs that Part D enrollees obtain are a step in the right direction. For now, the effect will likely be small[45] because patients already receive discounts on the listed drugs, bringing the net savings down substantially. However, the potential for real savings for Americans ages 65 and older will undoubtedly grow as more drugs become subject to negotiation.

At the same time, drug manufacturers have indicated that they are willing to take their legal battles against the Medicare drug pricing reform all the way to the Supreme Court[46]. If that happens, there’s a good chance they will prevail[47] because the arguments made in their lawsuits are likely to appeal to the Supreme Court’s conservative majority, which has been favorable[48] to many of the arguments made by drugmakers in their lawsuits.

Moreover, drugmakers could also simply pull their drugs from Medicare and Medicaid to force the government’s hand. The Centers for Medicare & Medicaid Services seems to have deliberately chosen drugs that make up a high percentage of manufacturers’ drug sales[49] to counter this possibility. The industry has a history of skillfully exploiting loopholes[50] and possesses a vast lobbying apparatus[51].

It’s also too soon to know if this is going to be a win for American patients overall. It’s possible that Americans who aren’t covered by Medicare may actually see prices go up[52]. That’s because if drugmakers do make less money on drugs for people enrolled in Part D, they might make up for those lost profits by charging more for drugs that other people depend on.

And lastly, it’s possible that there will be fewer new prescription drugs[53] – as an indirect result of this policy that’s supposed to improve access to health care – because it may reduce drugmakers incentives[54]. While the number of cases is likely small, it would potentially take a toll on patients who might have seen a cure to their disease – or some relief from their symptoms.

Read more …Medicare starts a long road to cutting prices for drugs, starting with 10 costing it $50.5 billion...

More Articles …